Jaguar Health(JAGX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Jaguar Health
JAGX.US
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
4.822 T
JAGX.USMarket value -Rank by Market Cap -/-

Financial Score

16/01/2026 Update
D
PharmaceuticalsIndustry
Industry Ranking167/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-481.00%E
    • Profit Margin-341.90%E
    • Gross Margin82.74%A
  • Growth ScoreC
    • Revenue YoY12.45%B
    • Net Profit YoY-6.76%C
    • Total Assets YoY-15.38%E
    • Net Assets YoY-72.03%E
  • Cash ScoreC
    • Cash Flow Margin-29.25%D
    • OCF YoY12.45%B
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreE
    • Gearing Ratio91.19%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12 Health Care Stocks Moving In Friday's Intraday Session

    In Friday's trading session, Venus Concept (VERO) saw a significant gain of 618.9%, reaching $10.28, while Jaguar Health (JAGX) rose 106.01% to $1.57. Other gainers included PainReform (PRFX) up 40.43% and ImmunityBio (IBRX) up 36.96%. Conversely, PAVmed (PAVM) experienced the largest drop, falling 23.8% to $6.67, followed by Nuwellis (NUWE) down 18.99%. Agape ATP (ATPC) and Prelude Therapeutics (PRLD) also saw declines of 16.67% and 14.66%, respectively.

    benzinga_article·
    US
    PRLD
    -10.00%
    US
    JAGX
    +83.13%
    US
    VERO
    +583.92%
    benzinga_article·
    US
    PRLD
    -10.00%
    US
    JAGX
    +83.13%
    US
    VERO
    +583.92%

    Jaguar Health shares are trading higher after the company announced its subsidiary, Napo Pharmaceuticals, entered into a license agreement with Woodward Specialty.

    benzinga_article·
    US
    JAGX
    +83.13%
    benzinga_article·
    US
    JAGX
    +83.13%

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    In Friday's pre-market session, Venus Concept (VERO) saw a significant gain of 149.7%, reaching $3.57, with a market cap of $2.6 million. Other gainers included ImmunityBio (IBRX) up 23.54% to $4.88, and Jaguar Health (JAGX) up 20.61% to $0.92. Conversely, Inspire Veterinary (IVP) dropped 12.8% to $0.04, while Agape ATP (ATPC) fell 12.28% to $0.1. Acurx Pharmaceuticals (ACXP) and Gelteq (GELS) also experienced declines of 8.93% and 8.88%, respectively.

    benzinga_article·
    US
    JAGX
    +83.13%
    US
    VERO
    +583.92%
    US
    IBRX
    +35.70%
    benzinga_article·
    US
    JAGX
    +83.13%
    US
    VERO
    +583.92%
    US
    IBRX
    +35.70%

    Jaguar Health Inc - Co & Unit Entered License Agreement With Woodward Specialty Llc - SEC Filing

    SEC Filing:JAGUAR HEALTH INC - CO & UNIT ENTERED LICENSE AGREEMENT WITH WOODWARD SPECIALTY LLC - SEC FILINGJAGUAR HEALTH INC - WOODWARD SPECIALTY TO PAY NAPO UPFRONT $18 MILLION INCLUDING $16 MILLION ON EFFECTIVE DATE - SEC FILINGJAGUAR HEALTH INC - NAPO HAS UNILATERAL RIGHT TO REBUY RIGHTS UNDER LICENSE AGREEMENT - SEC FILING

    Reuters·
    US
    JAGX
    +83.13%
    Reuters·
    US
    JAGX
    +83.13%

    Jaguar Health Signs $38 Million U.S. Licensing Deal With Future Pak for Crofelemer Products

    Jaguar Health Inc. has signed a $38 million licensing deal with Future Pak, LLC, allowing Future Pak to exclusively market Jaguar's Mytesi and Canalevia-CA1 products in the U.S. Jaguar will receive an $18 million upfront payment and up to $20 million in future milestone payments. The company will continue to manufacture the products and retains a 12-month right to reacquire product rights under certain conditions.

    Reuters·
    US
    JAGX
    +83.13%
    Reuters·
    US
    JAGX
    +83.13%
    © 2026 Longbridge｜Disclaimer